First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2

• Main Authors: Ian M. Catlett (Author), Urvi Aras (Author), Lars Hansen (Author), Yali Liu (Author), Di Bei (Author), Ihab G. Girgis (Author), Bindu Murthy (Author)
• Format: Book
• Published: Wiley, 2023-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract This randomized, double‐blind, single‐ and multiple‐ascending dose study assessed the pharmacokinetics (PKs), pharmacodynamics, and safety of deucravacitinib (Sotyktu™), a selective and potent small‐molecule inhibitor of tyrosine kinase 2, in 100 (75 active, 25 placebo) healthy volunteers (...